Statements made in this news release that are not historical facts, including statements concerning future treatment of patients using DCVax and future clinical trials, are forward-looking statements ...
BETHESDA, Md., Nov. 19, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, ...
DCVax ®-Direct offers a potential new treatment option for the wide range of clinical situations in which patients' tumors are considered "inoperable" because the patient has multiple tumors, or their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results